Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092228 | 0.79 | METAP2 (0.34) | — | |
| SCHEMBL2750506 | 0.79 | NOTUM (0.37) | NPC1RAB9AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL500129 | 0.78 | ALOX15 (0.41) | NPC1RAB9AKDM4EALDH1A1CYP2D6 | |
| SCHEMBL9955989 | 0.77 | NR4A1 (0.41) | KDM4ENOTUMTP53GABRPGABRD | |
| SCHEMBL2752150 | 0.73 | SLC9A1 (0.36) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL2752821 | 0.71 | NOTUM (0.44) | NOTUMAR | |
| SCHEMBL2752047 | 0.71 | AHR (0.46) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2751461 | 0.69 | PDE4B (0.32) | NPC1RAB9ALMNA | |
| SCHEMBL9956189 | 0.68 | NOTUM (0.38) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL2753597 | 0.67 | S1PR1 (0.34) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3880051-B2 | — | — | 2007-02-14 | — | — | JP | claimed |
| US-7138400-B2 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-21 | — | — | US | claimed |
| EP-1334085-B1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2005-08-24 | — | — | EP | claimed |
| JP-2004513108-A | — | — | 2004-04-30 | — | — | JP | claimed |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2004-03-11 | — | — | US | claimed |
| EP-1334085-A1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LTD. (GB) | 2003-08-13 | — | — | EP | claimed |
| WO-2002036555-A1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-10 | — | — | WO | claimed |
| US-8242103-B2 | Sulphamides for treatment of cancer | MERCK SHARP & DOHME LIMITED (GB) | 2012-08-14 | — | — | US | disclosed |
| WO-2012085852-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085857-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| EP-1885349-A2 | SULPHAMIDES FOR TREATMENT OF CANCER | Merck Sharp & Dohme Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006123185-A2 | SULPHAMIDES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
| US-7138400-B2 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-21 | — | — | US | disclosed |
| EP-1334085-B1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2005-08-24 | — | — | EP | disclosed |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2004-03-11 | — | — | US | disclosed |
| EP-1334085-A1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LTD. (GB) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002036555-A1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | SDHA, SDHB, BRDT | NPC1 3909/4885RAB9A 3104/4885KDM4E 1872/4885 |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | NPC1 2360/4885RAB9A 3262/4885KDM4E 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.